Clinical trial NCT03311295: MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States
Official title: MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Mitral Valve Insufficiency
Lead sponsor: Mvrx, Inc.
Sponsor class: INDUSTRY
First posted: 2017-10-17
Enrollment: 1
Sex: ALL
Minimum age (years): 21
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of the study is to evaluate the safety and feasibility of the ARTO System in patients with mitral valve regurgitation (MR) associated with congestive heart failure (CHF).


Eligibility criteria: Inclusion Criteria:

Candidates must meet ALL of the following criteria to be enrolled in the study.

* Is ambulatory, able and willing to comply with the study protocol and has provided written informed consent
* Age 21-85, inclusive
* Trans-septal catheterization is determined to be feasible by the treating physician
* NYHA class II-IV heart failure of any etiology
* Symptomatic with MR grade ≥ 2+
* LVEF \< 40%
* LVEDD \> 50 mm and ≤ 75 mm
* No anticipated change in patient's cardiac medication regimen anticipated throughout the course of the study.
* In the opinion of the investigator and heart surgery team, the patient is not an appropriate candidate for surgery, and the use of the ARTO System is technically feasible

Exclusion Criteria:

Candidates will be excluded from enrollment in the study if ANY of the following conditions apply.

* In the opinion of the Investigator, the femoral vein and internal jugular vein cannot accommodate a 16 F catheter or the presence of an inferior vena cava (IVC) filter would interfere with advancement of the catheter or ipsilateral DVT is present
* Significant structural abnormality of the mitral valve (e.g., flail, prolapse, leaflet calcification)
* Significant mitral annular calcification
* Hemodynamic instability (systolic pressure \< 90 mmHg without afterload reduction or cardiogenic shock or the need for inotropic support or intra-aortic balloon pump)
* Prior mitral valve surgery or valvuloplasty or any currently implanted prosthetic valve or VAD
* History of, or active, rheumatic heart disease
* History of Atrial Septal Defects (ASD), whether repaired or not
* History of previously repaired PFO or PFO associated with clinical symptoms (e.g., cerebral ischemia) within 6 months of the planned investigational procedure
* In the opinion of the investigator, an atrial septal aneurysm is present that may interfere with transseptal crossing
* Serum creatinine \> 2.5 mg/dL or dialysis dependent
* No access to coronary sinus and/or great cardiac vein
* Platelet count \< 100 x 103 cells/mm3
* Evidence of active infection (fever with temperature \> 38°C and/or WBC \> 15,000) or endocarditis
* Echocardiographic evidence of mass intracardiac thrombus
* Patients on prescribed dual antiplatelet therapy (asprin + any P2Y12 inhibitor) that cannot be discontinued.
* Percutaneous coronary intervention or surgery anticipated within the 6 month follow up period following the investigational procedure
* Biventricular pacing initiated or anticipated within 6 months of the planned investigational procedure
* Evidence of an acute myocardial infarction within 12 weeks of the planned investigational procedure
* Stroke or TIA within 6 months of the planned investigational procedure
* GI bleeding within 6 months of the planned investigational procedure
* Intravenous drug abuse or suspected inability to adhere to follow-up
* Patients in whom TTE, TEE or ICE is contraindicated
* Contraindication to CT scan
* A known hypersensitivity or contraindication to study or procedure medications (specifically aspirin, clopidogrel and heparin) that cannot be adequately managed medically
* A known allergy or hypersensitivity to nickel
* A known need for any other cardiac surgery including surgery for coronary artery disease, atrial fibrillation, pulmonic, aortic or tricuspid valve disease
* In the judgment of the Investigator, patients in whom the presence of a permanent pacemaker or pacing leads would interfere with placement of the test device or the placement of the test device would disrupt the leads
* Irreversible bleeding disorder, history of bleeding diathesis or coagulopathy or refuses blood transfusion
* Evidence of disease or condition expected to compromise survival (\< 1 year) or ability to complete follow-up assessments
* Pregnant or breastfeeding women
* Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. \[Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials\]
* Patient not a candidate for emergent surgical bailout in case of need

Primary outcomes:
measure: Safety: Major Adverse Event Rate to 30 Days post-procedure
timeFrame: 30 days post procedure
measure: Efficacy: Mitral regurgitation grade by ASE criteria and change from baseline to 1 year
timeFrame: Baseline to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: UC Davis Medical Center
state: California
Study officials:
affiliation: University California Davis
name: Reginald Low, MD
role: PRINCIPAL_INVESTIGATOR
References: